CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential.
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
赖氨酸特异性去甲基化酶1(LSD1)是一种从核小体组蛋白尾部去除赖氨酸甲基化标记的酶,在癌症的发生、进展、转移和复发中发挥重要作用。近年来的研究表明,LSD1通过多条上游和下游通路调控肿瘤细胞和免疫细胞,使肿瘤细胞能够适应肿瘤微环境(TME)。作为一种潜在的抗肿瘤治疗策略,免疫治疗在过去几年中发展迅速。然而,由于存在广泛的免疫抑制机制,大多数患者对现有免疫检查点抑制剂(ICIs)的缓解率较低,包括抗PD-(L)1治疗和CAR-T 细胞治疗。值得注意的是,抑制LSD1可将“冷肿瘤”转化为“热肿瘤”,进而增强肿瘤细胞对ICIs的敏感性。本综述聚焦于LSD1与肿瘤免疫的最新进展,并探讨将LSD1抑制与免疫治疗联合的潜在治疗策略。
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years.
However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms.
Notably, inhibition of LSD1 turns "cold tumors" into "hot tumors" and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。